المؤلفون: Heidemarie Haller, Petra Voiß, Holger Cramer, Anna Paul, Mattea Reinisch, Sebastian Appelbaum, Gustav Dobos, Georg Sauer, Sherko Kümmel, Thomas Ostermann

المصدر: BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)

مصطلحات موضوعية: Breast Cancer, Predictors, Treatment response, Integrative Cancer treatment, Complementary medicine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Cancer registries usually assess data of conventional treatments and/or patient survival. Beyond that, little is known about the influence of other predictors of treatment response related to the use of complementary therapies (CM) and lifestyle factors affecting patients’ quality and quantity of life. Methods INTREST is a prospective cohort study collecting register data at multiple German certified cancer centers, which provide individualized, integrative, in- and outpatient breast cancer care. Patient-reported outcomes and clinical cancer data of anticipated N = 715 women with pTNM stage I-III breast cancer are collected using standardized case report forms at the time of diagnosis, after completing neo−/adjuvant chemotherapy, after completing adjuvant therapy (with the exception of endocrine therapy) as well as 1, 2, 5, and 10 years after baseline. Endpoints for multivariable prediction models are quality of life, fatigue, treatment adherence, and progression-based outcomes/survival. Predictors include the study center, sociodemographic characteristics, histologic cancer and comorbidity data, performance status, stress perception, depression, anxiety, sleep quality, spirituality, social support, physical activity, diet behavior, type of conventional treatments, use of and belief in CM treatments, and participation in a clinical trial. Safety is recorded following the Common Terminology Criteria for Adverse Events. Discussion This trial is currently recruiting participants. Future analyses will allow to identify predictors of short- and long-term response to integrative breast cancer treatment in women, which, in turn, may improve cancer care as well as quality and quantity of life with cancer. Trial registration German Clinical Trial Register DRKS00014852 . Retrospectively registered at July 4th, 2018.

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1471-2407

URL الوصول: https://doaj.org/article/42b9df6384204ef999b1c24080ba0422

المؤلفون: Haller, Heidemarie^Aff1, Voiß, Petra^{Aff1, Aff2}, Cramer, Holger, Paul, Anna, Reinisch, Mattea, Appelbaum, Sebastian, Dobos, Gustav, Sauer, Georg, Kümmel, Sherko, Ostermann, Thomas

المصدر: BMC Cancer. 21(1)

المؤلفون: Mattea Reinisch, Sherko Kümmel, Sebastian Appelbaum, Gustav Dobos, Anna Paul, Petra Voiß, Heidemarie Haller, Holger Cramer, Thomas Ostermann, Georg Sauer

المصدر: BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)

مصطلحات موضوعية: Complementary Therapies, Cancer Research, medicine.medical_specialty, Medizin, Breast Neoplasms, Treatment response, Cohort Studies, 03 medical and health sciences, Study Protocol, 0302 clinical medicine, Breast cancer, Quality of life, Internal medicine, Breast Cancer, Genetics, medicine, Adjuvant therapy, Humans, 030212 general & internal medicine, Prospective Studies, Registries, Prospective cohort study, RC254-282, Performance status, business.industry, Predictors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Cancer, Common Terminology Criteria for Adverse Events, medicine.disease, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Integrative Cancer treatment, Female, business, Complementary medicine

الوصف: Background Cancer registries usually assess data of conventional treatments and/or patient survival. Beyond that, little is known about the influence of other predictors of treatment response related to the use of complementary therapies (CM) and lifestyle factors affecting patients’ quality and quantity of life. Methods INTREST is a prospective cohort study collecting register data at multiple German certified cancer centers, which provide individualized, integrative, in- and outpatient breast cancer care. Patient-reported outcomes and clinical cancer data of anticipated N = 715 women with pTNM stage I-III breast cancer are collected using standardized case report forms at the time of diagnosis, after completing neo−/adjuvant chemotherapy, after completing adjuvant therapy (with the exception of endocrine therapy) as well as 1, 2, 5, and 10 years after baseline. Endpoints for multivariable prediction models are quality of life, fatigue, treatment adherence, and progression-based outcomes/survival. Predictors include the study center, sociodemographic characteristics, histologic cancer and comorbidity data, performance status, stress perception, depression, anxiety, sleep quality, spirituality, social support, physical activity, diet behavior, type of conventional treatments, use of and belief in CM treatments, and participation in a clinical trial. Safety is recorded following the Common Terminology Criteria for Adverse Events. Discussion This trial is currently recruiting participants. Future analyses will allow to identify predictors of short- and long-term response to integrative breast cancer treatment in women, which, in turn, may improve cancer care as well as quality and quantity of life with cancer. Trial registration German Clinical Trial Register DRKS00014852. Retrospectively registered at July 4th, 2018.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc4df81b287f9d987770402f713ddf97
https://pubmed.ncbi.nlm.nih.gov/34162339

المؤلفون: Mark Levine, Lisa Spruce, Qi Chen, Jeanne Drisko, Oscar K. Serrano

المصدر: Anti-Cancer Drugs

مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, vitamin C, Ascorbic Acid, Case Reports, Gastroenterology, Sepsis, 03 medical and health sciences, intravenous ascorbate, intravenous vitamin C, 0302 clinical medicine, intravenous ascorbic acid, Positron Emission Tomography Computed Tomography, Internal medicine, Pancreatic cancer, medicine, Carcinoma, Humans, Pharmacology (medical), integrative cancer treatment, Dosing, Aged, Pharmacology, Integrative Medicine, Chemotherapy, business.industry, biochemical phenomena, metabolism, and nutrition, Prognosis, medicine.disease, Ascorbic acid, Pancreatic Neoplasms, Biliary Tract Surgical Procedures, Regimen, 030104 developmental biology, Oncology, Tumor progression, 030220 oncology & carcinogenesis, Disease Progression, Administration, Intravenous, Stents, pancreatic cancer treatment, business, Carcinoma, Pancreatic Ductal

الوصف: Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis and is often discovered at an advanced stage with few therapeutic options. Current conventional regimens for PDA are associated with significant morbidity, decreased quality of life, and a considerable financial burden. As a result, some patients turn to integrative medicine therapies as an alternate option after a diagnosis of PDA. Intravenous pharmacologic ascorbic acid (PAA) is one such treatment. The use of PAA has been passionately debated for many years, but more recent rigorous scientific research has shown that there are significant blood concentration differences when ascorbic acid is given parenterally when compared to oral dosing. This pharmacologic difference appears to be critical for its role in oncology. Here, we report the use of PAA in a patient with poorly differentiated stage IV PDA as an exclusive chemotherapeutic regimen. The patient survived nearly 4 years after diagnosis, with PAA as his sole treatment, and he achieved objective regression of his disease. He died from sepsis and organ failure from a bowel perforation event. This case illustrates the possibility of PAA to effectively control tumor progression and serve as an adjunct to standard of care PDA chemotherapy regimens. Our patient’s experience with PAA should be taken into consideration, along with previous research in cell, animal, and clinical experiments to design future treatment trials.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eb04533c084f63ef49eb31d447aaa21
https://doi.org/10.1097/cad.0000000000000603

المؤلفون: Eberhard, Ulrich^Aff1

المصدر: Deutsche Zeitschrift für Akupunktur: German Journal for Acupuncture and related techniques. 59(2):48-49

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Chong-Kwan Cho, Hwa-Seung Yoo, Jong-Min Kim

المصدر: Integrative Cancer Therapies

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Lung Neoplasms, herbal medication, overall survival, Cancer therapy, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, 030212 general & internal medicine, integrative cancer treatment, Adverse effect, Lung cancer, Survival rate, Survival analysis, Research Articles, Aged, Aged, 80 and over, business.industry, Cancer, Middle Aged, medicine.disease, Survival Analysis, Confidence interval, Surgery, Survival Rate, Complementary and alternative medicine, Oncology, quality of life, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, advanced non–small cell lung cancer, Female, Non small cell, business, Wheel Balance Cancer Therapy

الوصف: Objective. To investigate the clinical effect and the overall survival (OS) rate of patients with advanced non–small cell lung cancer (NSCLC) who have undergone Wheel Balance Cancer Therapy (WBCT). Methods. The cases of 33 patients with advanced NSCLC who were treated with WBCT at the East West Cancer Center (EWCC) between October 4, 2004, and October 3, 2013, without undergoing concurrent conventional treatment were analyzed. The Kaplan-Meier method was used to estimate the OS of the cases, and the median OS was calculated according to age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), conventional-treatment history, WBCT treatment duration, and histological tumor type. Results. The median OS of all patients was 31.1 (95% confidence interval [CI] = 3.5-58.7) months; the OS rates were 63.6% and 24.2% at years 1 and 2, respectively. The median OS rates of patients under and over 65 years were 45.2 (95% CI = 13.5-76.9) and 19.5 (95% CI = 7.1-31.8) months, respectively ( P = .189). The median OS rates of patients who received WBCT for >14 days but

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11fc555ec961c19310054ff90dd0db6e
https://pubmed.ncbi.nlm.nih.gov/27151594

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.